Not provided
Not provided
Not provided
Not provided
Not provided
Recruitment issues
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to evaluate if postoperative antibiotic use in patients with mandible trauma reduce the risk of postoperative infections and does the benefit differ based on severity, soft tissue loss, other concomitant injuries, and medical problems
The purpose of this study is to evaluate the use of antibiotics postoperatively in non-infected mandible fractures compared to the lack of postoperative antibiotics in the same population.
The first outcome measure is infection. Evidence of infection includes persistent swelling, fever, recurrent swelling, erythema, and purulent discharge.
The second outcome measure is no infection. Absence of persistent swelling, fever, recurrent swelling, erythema, and purulent discharge.
Outcome measures will be assessed on follow-up visits: post op week 1, post op week 3, and post op week 6-8. Latest follow-up is up to 8 weeks. If the subject presents with any of the above mentioned symptoms during the 8 week post-op period, the subject will be considered positive for infection.
Prospective randomized trial: Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care. Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.
The patient will follow up post op week 1, post op week 3, and post op week 6-8. Latest follow-up is up to 8 weeks.
Patients will be monitored for any complications, including reaction to IV and oral antibiotics. Patient will assessed after the one-time post-op IV antibiotic dose and during their follow-up visits at weeks 1, 3, and 6-8.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment | Experimental | Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days. |
|
| Control | Active Comparator | Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antibiotic treatment (Unasyn or Cleocin) | Drug | Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evidence of infection as measured by presence of persistent swelling, | post treatment week1 | |
| Evidence of infection as measured by presence of persistent swelling, | post treatment week 3 | |
| Evidence of infection as measured by presence of persistent swelling, | post treatment week 6-8 | |
| Evidence of infection as measured by presence of fever | post treatment week 1 | |
| Evidence of infection as measured by presence of fever | post treatment week 3 | |
| Evidence of infection as measured by presence of fever | post treatment week 6-8 | |
| Evidence of infection as measured by presence of recurrent swelling | post treatment week 1 | |
| Evidence of infection as measured by presence of recurrent swelling | post treatment week 3 | |
| Evidence of infection as measured by presence of recurrent swelling | post treatment week 6-8 | |
| Evidence of infection as measured by presence of erythema | post treatment week 1 |
| Measure | Description | Time Frame |
|---|---|---|
| No evidence of infection as measured by absence of persistent swelling | post treatment week 1 | |
| No evidence of infection as measured by absence of persistent swelling | post treatment week 3 | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Age - < 18 years
Pregnancy
Fracture Site - closed / non-dentate eg. Condylar neck, edentulous
Soft Tissue Injury - > Grade 4 (GSW)
Allergic to all study drugs
Medical Problems
Interval - Injury to Surgery - > 10days
Already receiving antibiotics for
Inability to provide informed consent.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nagi Demian, DDS/MD | The University of Texas Health Science Center, Houston | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Memorial Hermann Hospital | Houston | Texas | 77030 | United States | ||
| Th University of Texas Health Science Center at Houston |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Antibiotic treatment (Augmentin or Cleocin) | Drug | the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). |
|
|
| Control Group | Other | Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care |
|
| Evidence of infection as measured by presence of erythema | post treatment week 3 |
| Evidence of infection as measured by presence of erythema | post treatment week 6-8 |
| Evidence of infection as measured by presence of purulent discharge | post treatment week 1 |
| Evidence of infection as measured by presence of purulent discharge | post treatment week 3 |
| Evidence of infection as measured by presence of purulent discharge | post treatment week 6-8 |
| No evidence of infection as measured by absence of persistent swelling |
| post treatment week 6-8 |
| No evidence of infection as measured by absence of fever | post treatment week 1 |
| No evidence of infection as measured by absence of fever | post treatment week 3 |
| No evidence of infection as measured by absence of fever | post treatment week 6-8 |
| No evidence of infection as measured by absence of recurrent swelling | post treatment week 1 |
| No evidence of infection as measured by absence of recurrent swelling | post treatment week 3 |
| No evidence of infection as measured by absence of recurrent swelling | post treatment week 6-8 |
| No evidence of infection as measured by absence of erythema | post treatment week 1 |
| No evidence of infection as measured by absence of erythema | post treatment week 3 |
| No evidence of infection as measured by absence of erythema | post treatment week 6-8 |
| No evidence of infection as measured by absence of purulent discharge | post treatment week 1 |
| No evidence of infection as measured by absence of purulent discharge | post treatment week 3 |
| No evidence of infection as measured by absence of purulent discharge | post treatment week 6-8 |
| Houston |
| Texas |
| 77030 |
| United States |
| ID | Term |
|---|---|
| D007572 | Jaw Fractures |
| D007239 | Infections |
| ID | Term |
|---|---|
| D008446 | Maxillofacial Injuries |
| D005151 | Facial Injuries |
| D006259 | Craniocerebral Trauma |
| D020196 | Trauma, Nervous System |
| D009422 | Nervous System Diseases |
| D012887 | Skull Fractures |
| D050723 | Fractures, Bone |
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| C035444 | sultamicillin |
| D002981 | Clindamycin |
| D019980 | Amoxicillin-Potassium Clavulanate Combination |
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D008034 | Lincomycin |
| D055231 | Lincosamides |
| D011759 | Pyrrolidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D019818 | Clavulanic Acid |
| D002969 | Clavulanic Acids |
| D047090 | beta-Lactams |
| D007769 | Lactams |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000658 | Amoxicillin |
| D000667 | Ampicillin |
| D010400 | Penicillin G |
| D010406 | Penicillins |
| D013457 | Sulfur Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
| D008722 | Methods |
Not provided
Not provided